TYRP1 and neoplasm: These changes in the TME do not appear to relate to direct effects of the 2.5F-Fc molecule on tumor ECs, as AIP therapy using the TYRP-1-specific TA99 antibody instead of 2.5F-Fc elicited similar changes in B16F10 tumors (Figure S7A).